Cited by 124Cardiomyopathy and Myosin StudiesCardiac electrophysiology and arrhythmiasCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Contractile Dysfunction Irrespective of the Mutant Protein in Human Hypertrophic Cardiomyopathy With Normal Systolic Function

Open access

van Dijk, Sabine J., Paalberends, E. Rosalie, Najafi, Aref, Michels, Michelle, Sadayappan, Sakthivel, Carrier, Lucie, Boontje, Nicky M., Kuster, Diederik W.D., van Slegtenhorst, Marjon, Dooijes, Dennis, dos Remedios, Cris, ten Cate, Folkert J., Stienen, Ger J.M., van der Velden, Jolanda·2012·Circulation: Heart Failure

DOI 10.1161/circheartfailure.111.963702

Open this paper in CoChat — free account Open PDF

Abstract

Background—: Hypertrophic cardiomyopathy (HCM), typically characterized by asymmetrical left ventricular hypertrophy, frequently is caused by mutations in sarcomeric proteins. We studied if changes in sarcomeric properties in HCM depend on the underlying protein mutation. Methods and Results—: Comparisons were made between cardiac samples from patients carrying a MYBPC3 mutation (MYBPC3 mut ; n=17), mutation negative HCM patients without an identified sarcomere mutation (HCM mn ; n=11), and nonfailing donors (n=12). All patients had normal systolic function, but impaired diastolic function. Protein expression of myosin binding protein C (cMyBP-C) was significantly lower in MYBPC3 mut by 33±5%, and similar in HCM mn compared with donor. cMyBP-C phosphorylation in MYBPC3 mut was similar to donor, whereas it was significantly lower in HCM mn . Troponin I phosphorylation was lower in both patient groups compared with donor. Force measurements in single permeabilized cardiomyocytes demonstrated comparable sarcomeric dysfunction in both patient groups characterized by lower maximal force generating capacity in MYBPC3 mut and HCM mn, compared with donor (26.4±2.9, 28.0±3.7, and 37.2±2.3 kN/m 2 , respectively), and higher myofilament Ca 2+ -sensitivity (EC 50 =2.5±0.2, 2.4±0.2, and 3.0±0.2 μmol/L, respectively). The sarcomere length-dependent increase in Ca 2+ -sensitivity was significantly smaller in both patient groups compared with donor (ΔEC 50 : 0.46±0.04, 0.37±0.05, and 0.75±0.07 μmol/L, respectively). Protein kinase A treatment restored myofilament Ca 2+ -sensitivity and length-dependent activation in both patient groups to donor values. Conclusions—: Changes in sarcomere function reflect the clinical HCM phenotype rather than the specific MYBPC3 mutation. Hypocontractile sarcomeres are a common deficit in human HCM with normal systolic left ventricular function and may contribute to HCM disease progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.111.963702

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cardiac excitation–contraction coupling
Bers, D., & Despa, S. (2002) · Nature · doi:10.1038/415198a · Cited by 4,927
Clinical Utility of Doppler Echocardiography and Tissue Doppler Imaging in the Estimation of Left Ventricular Filling Pressures: A Comparative Simultaneous Doppler-Catheterization Study
Ommen, S. R., Nishimura, R. A., Appleton, C. P., Miller, F. A., Oh, J. K., Redfield, M. M., & Tajik, A. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1788 · Cited by 2,790
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy
Maron, B. J., McKenna, W. J., Danielson, G. K., KAPPENBERGER, L. J., Kuhn, H. J., Seidman, C. E., Shah, P. M., Spencer, W. H., Spirito, P., ten Cate, F. J., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00941-0 · Cited by 1,572
Hypertrophic Cardiomyopathy
Richard, P., Charron, P., Carrier, L., Ledeuil, C., Cheav, T., Pichereau, C., Benaiche, A., Isnard, R., Dubourg, O., Burban, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000066323.15244.54 · Cited by 1,276
Self-citation
Phosphate-binding Tag, a New Tool to Visualize Phosphorylated Proteins
Kinoshita, E., Kinoshita‐Kikuta, E., Takiyama, K., & Koike, T. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t500024-mcp200 · Cited by 1,112
Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy
Ho, C. Y., López, B., Coelho‐Filho, O. R., Lakdawala, N. K., Cirino, A. L., Jarolı́m, P., Kwong, R. Y. K., González, A., Colan, S. D., Seidman, J. G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002659 · Cited by 697
Cardiomyocyte stiffness in diastolic heart failure
Borbély, A., van der Velden, J., Papp, Z., Bronzwaer, J. G. F., Edes, I., Stienen, G. J. M., & Paulus, W. J. (2005) · Circulation · doi:10.1161/01.cir.0000155257.33485.6d · Cited by 536
Self-citation
Phosphorylation switches specific for the cardiac isoform of myosin binding protein‐C: a modulator of cardiac contraction?
Gautel, M., Zuffardi, O., Freiburg, A., & Labeit, S. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07187.x · Cited by 414
A practical approach to the echocardiographic evaluation of diastolic function
Khouri, S. J., Maly, G., Suh, D. D., & Walsh, T. E. (2004) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2003.08.012 · Cited by 402
Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics
Alcalai, R., Seidman, J. G., & Seidman, C. E. (2007) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2007.00965.x · Cited by 387

Show all 51 references

Research works printed but not linked: 2

10.1016/S0025-6196(11)60890-2 · DOI
10.1161/circ.120.suppl_18.S870-b · DOI

Sorted by citations

Small and large animal models in cardiac contraction research: advantages and disadvantages
Milani-Nejad, N., & Janssen, P. M. L. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.007 · Cited by 484
Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology
Carrier, L., Mearini, G., Σταθοπούλου, Κ., & Cuello, F. (2015) · Gene · doi:10.1016/j.gene.2015.09.008 · Cited by 234
Self-citation
Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy
van Spaendonck‐Zwarts, K. Y., Pósafalvi, A., van den Berg, M. P., Hilfiker‐Kleiner, D., Bollen, I. A. E., Sliwa, K. S., Alders, M. M., Almomani, R., van Langen, I. M., van der Meer, P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu050 · Cited by 220
FRET biosensor uncovers cAMP nano-domains at β-adrenergic targets that dictate precise tuning of cardiac contractility
Surdo, N. C., Berrera, M., Koschinski, A., Brescia, M., Machado, M. R., Carr, C. A., Wright, P., Gorelik, J., Morotti, S., Grandi, E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15031 · Cited by 221
Perturbed Length-Dependent Activation in Human Hypertrophic Cardiomyopathy With Missense Sarcomeric Gene Mutations
Sequeira, V., Wijnker, P. J. M., Nijenkamp, L. L. A. M., Kuster, D. W. D., Najafi, A., Witjas‐Paalberends, E. R., Regan, J. A., Boontje, N. M., ten Cate, F. J., Germans, T., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300436 · Cited by 196
Self-citation
The physiological role of cardiac cytoskeleton and its alterations in heart failure
Sequeira, V., Nijenkamp, L. L. A. M., Regan, J. A., & van der Velden, J. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.07.011 · Cited by 198
Crucial Role for Ca 2+ /Calmodulin-Dependent Protein Kinase-II in Regulating Diastolic Stress of Normal and Failing Hearts via Titin Phosphorylation
Hamdani, N., Krysiak, J., Kreußer, M. M., Neef, S., dos Remedios, C. G., Maier, L. S., Krüger, M., Backs, J., & Linke, W. A. (2013) · Circulation Research · doi:10.1161/circresaha.111.300105 · Cited by 186
Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice
Mearini, G., Stimpel, D., Geertz, B., Weinberger, F., Krämer, E., Schlossarek, S., Mourot-Filiatre, J., Stoehr, A., Dutsch, A., Wijnker, P. J. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6515 · Cited by 172
Self-citation
Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice
Fraysse, B., Weinberger, F., Bardswell, S. C., Cuello, F., Vignier, N., Geertz, B., Starbatty, J., Krämer, E., Coirault, C., Thomas Eschenhagen, A., et al. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.009 · Cited by 140
Self-citation
Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations
Witjas‐Paalberends, E. R., Güçlü, A., Germans, T., Knaapen, P., Harms, H. J., Vermeer, A. M. C., Christiaans, I., Wilde, A. A. M., dos Remedios, C. G., Lammertsma, A. A., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu127 · Cited by 130
Self-citation
Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy
Friedrich, F. W., Wilding, B. R., Reischmann, S., Crocini, C., Lang, P. M., Charron, P., Müller, O. J., McGrath, M. J., Vollert, I., Hansen, A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds157 · Cited by 119
Self-citation
Phosphorylation of cardiac Myosin-binding protein-C is a critical mediator of diastolic function
Rosas, P. C., Liu, Y., Abdalla, M. I., Thomas, C. M., Kidwell, D. T., Dusio, G. F., Mukhopadhyay, D., Kumar, R., Baker, K. M., Mitchell, B. M., et al. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001550 · Cited by 112
Contractile Dysfunction of Left Ventricular Cardiomyocytes in Patients With Pulmonary Arterial Hypertension
Manders, E., Bogaard, H. J., Handoko, M. L., van de Veerdonk, M. C., KEOGH, A. M., Westerhof, N., Stienen, G. J. M., dos Remedios, C. G., Humbert, M. J. C., Dorfmüller, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.031 · Cited by 112
Self-citation
A mutation in the glutamate-rich region of RNA-binding motif protein 20 causes dilated cardiomyopathy through missplicing of titin and impaired Frank–Starling mechanism
Beqqali, A., Bollen, I. A. E., Rasmussen, T. B., van den Hoogenhof, M. M. G., van Deutekom, H. W. M., Schäfer, S., Haas, J., Meder, B., Sørensen, K. E., van Oort, R. J., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw192 · Cited by 110
Cardiac Disorders and Pathophysiology of Sarcomeric Proteins
van der Velden, J., & Stienen, G. J. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00040.2017 · Cited by 117
Self-citation
Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy
Previs, M. J., O’Leary, T. S., Morley, M. P., Morley, M. P., Palmer, B., Lewinter, M., Pagani, F. D., Pagani, F. D., Petucci, C., Kim, M., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009521 · Cited by 108
Mutation‐Specific Phenotypes in hiPSC‐Derived Cardiomyocytes Carrying Either Myosin‐Binding Protein C Or α ‐Tropomyosin Mutation for Hypertrophic Cardiomyopathy
Ojala, M., Prajapati, C., Pölönen, R.-P., Rajala, K., Pekkanen-Mattila, M., Rasku, J., Larsson, K., & Aalto‐Setälä, K. (2015) · Stem Cells International · doi:10.1155/2016/1684792 · Cited by 107
Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology
van der Velden, J., Tocchetti, C. G., Varricchi, G., Bianco, A., Sequeira, V., Hilfiker‐Kleiner, D., Hamdani, N., Leite-Moreira, A. F., Mayr, M., Falcão‐Pires, I., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy147 · Cited by 103
Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy
Witjas‐Paalberends, E. R., Piroddi, N., Stam, K., van Dijk, S. J., Sequeira, V., Ferrara, C., Scellini, B., Hazebroek, M. R., ten Cate, F. J., van Slegtenhorst, M., et al. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt119 · Cited by 103
Self-citation
Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in mice
Gedicke, C., Behrens‐Gawlik, V., Reischmann, S., Geertz, B., Stimpel, D., Weinberger, F., Schlossarek, S., Précigout, G., Braren, I., Thomas Eschenhagen, A., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202168 · Cited by 101
Self-citation
Sarcomere Mutation-Specific Expression Patterns in Human Hypertrophic Cardiomyopathy
Helms, A. S., Davis, F. M., Coleman, D., Bartolone, S. N., Glazier, A. A., Pagani, F. D., Yob, J. M., Sadayappan, S., Pedersen, E. B., Lyons, R., et al. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000448 · Cited by 101
Self-citation
Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy
Helms, A. S., Tang, V. T., O’Leary, T. S., Friedline, S., Wauchope, M., Arora, A., Wasserman, A. H., Smith, E. D., Lee, L. M., Wen, X., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.133782 · Cited by 96
Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits
Wijnker, P. J. M., Sequeira, V., Kuster, D. W. D., & van der Velden, J. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7236 · Cited by 90
Self-citation
Cardiomyopathies and Related Changes in Contractility of Human Heart Muscle
Vikhorev, P. G., & Vikhoreva, N. N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082234 · Cited by 85
Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients
Nag, S., Gollapudi, S. K., del Rio, C. L., Spudich, J. A., & McDowell, R. E. (2023) · Science Advances · doi:10.1126/sciadv.abo7622 · Cited by 80
Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes—a systematic review
Eschenhagen, T., & Carrier, L. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2214-0 · Cited by 82
Self-citation
Proteasome dysfunction in cardiomyopathies
Gilda, J. E., & Gomes, A. V. (2017) · The Journal of Physiology · doi:10.1113/jp273607 · Cited by 77
Sex Differences at the Time of Myectomy in Hypertrophic Cardiomyopathy
Nijenkamp, L. L. A. M., Bollen, I. A. E., van Velzen, H. G., Regan, J. A., van Slegtenhorst, M., Niessen, H. W. M., Schinkel, A. F. L., Krüger, M., Poggesi, C., Ho, C. Y., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004133 · Cited by 71
Self-citation
Ubiquitin-proteasome system and hereditary cardiomyopathies
Schlossarek, S., Frey, N., & Carrier, L. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.12.016 · Cited by 69
Self-citation
FHL2 expression and variants in hypertrophic cardiomyopathy
Friedrich, F. W., Reischmann, S., Schwalm, A., Unger, A., Ramanujam, D. P., Münch, J., Müller, O. J., Hengstenberg, C., Galve, E., Charron, P., et al. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0451-8 · Cited by 68
Self-citation
Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2–Mediated COVID-19
Bos, J. M., Hebl, V. B., Oberg, A. L., Sun, Z., Herman, D. S., Teekakirikul, P., Seidman, J. G., Seidman, C. E., dos Remedios, C. G., Maleszewski, J. J., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.04.028 · Cited by 64
Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy
Glazier, A. A., Thompson, A. D., & Day, S. M. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2226-9 · Cited by 63
MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations
Kuster, D. W. D., Mulders, J., ten Cate, F. J., Michels, M., dos Remedios, C. G., Martins, P. A. D. C., van der Velden, J., & Oudejans, C. B. M. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.09.012 · Cited by 62
Self-citation
Familial hypertrophic cardiomyopathy: Functional effects of myosin mutation R723G in cardiomyocytes
Kraft, T., Witjas‐Paalberends, E. R., Boontje, N. M., Tripathi, S., Brandis, A., Montag, J., Hodgkinson, J. L., Francino, A., Navarro‐López, F., Brenner, B., et al. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.01.001 · Cited by 61
Self-citation
Cardiac Myosin Binding Protein-C Phosphorylation Modulates Myofilament Length-Dependent Activation
Mamidi, R., Gresham, K. S., Verma, S., & Stelzer, J. E. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00038 · Cited by 57
GSK3β Phosphorylates Newly Identified Site in the Proline-Alanine–Rich Region of Cardiac Myosin–Binding Protein C and Alters Cross-Bridge Cycling Kinetics in Human
Kuster, D. W. D., Sequeira, V., Najafi, A., Boontje, N. M., Wijnker, P. J. M., Witjas‐Paalberends, E. R., Marston, S. B., dos Remedios, C. G., Carrier, L., Demmers, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.112.275602 · Cited by 55
Self-citation
Impact of the Myosin Modulator Mavacamten on Force Generation and Cross‐Bridge Behavior in a Murine Model of Hypercontractility
Mamidi, R., Li, J., Doh, C. Y., Verma, S., & Stelzer, J. E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009627 · Cited by 55
Animal and in silico models for the study of sarcomeric cardiomyopathies
Duncker, D. J., Bakkers, J., Brundel, B. J. J. M., Robbins, J. M., Tardiff, J. C., & Carrier, L. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv006 · Cited by 56
Self-citation
AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models
Greer-Short, A., Greenwood, A., Leon, E. C., Qureshi, T. N., von Kraut, K., Wong, J., Tsui, J. H., Reid, C. A., Cheng, Z., Easter, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57481-7 · Cited by 56
Research priorities in sarcomeric cardiomyopathies
van der Velden, J., Ho, C. Y., Tardiff, J. C., Olivotto, I., Knollmann, B. C., & Carrier, L. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv019 · Cited by 53
Self-citation
Contractile dysfunction in a mouse model expressing a heterozygousMYBPC3mutation associated with hypertrophic cardiomyopathy
Barefield, D. Y., Kumar, M., de Tombe, P. P., & Sadayappan, S. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00913.2013 · Cited by 53
Self-citation
Hypertrophic Cardiomyopathy
Kraft, T., Montag, J., Radocaj, A., & Brenner, B. (2016) · Circulation Research · doi:10.1161/circresaha.116.309804 · Cited by 53
Impact of site-specific phosphorylation of protein kinase A sites Ser23and Ser24of cardiac troponin I in human cardiomyocytes
Wijnker, P. J. M., Foster, D. B., Tsao, A. L., Frazier, A. H., dos Remedios, C. G., Murphy, A. M., Stienen, G. J. M., & van der Velden, J. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00498.2012 · Cited by 50
Self-citation
Burst-Like Transcription of Mutant and Wildtype MYH7-Alleles as Possible Origin of Cell-to-Cell Contractile Imbalance in Hypertrophic Cardiomyopathy
Montag, J., Kowalski, K., Makul, M., Ernstberger, P., Radocaj, A., Beck, J., Becker, E., Tripathi, S., Keyser, B., Mühlfeld, C., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00359 · Cited by 49
MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction
Behrens‐Gawlik, V., Mearini, G., Gedicke, C., Richard, P., & Carrier, L. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1409-7 · Cited by 47
Self-citation
Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy
Ormerod, J. O. M., Frenneaux, M. P., & Sherrid, M. V. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.98 · Cited by 46
Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes
da Rocha, A. M., Guerrero‐Serna, G., Helms, A. S., Luzod, C., Mironov, S. V., Russell, M. W. W., Jalife, J., Day, S. M., Smith, G. D., & Herron, T. J. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.09.004 · Cited by 46
Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue
Crocini, C., Arimura, T., Reischmann, S., Eder, A., Braren, I., Hansen, A., Thomas Eschenhagen, A., Kimura, A., & Carrier, L. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0349-x · Cited by 45
Self-citation
Impaired contractile function due to decreased cardiac myosin binding protein C content in the sarcomere
Cheng, Y., Wan, X., McElfresh, T. A., Chen, X., Gresham, K. S., ROSENBAUM, D. S., Chandler, M. P., & Stelzer, J. E. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00929.2012 · Cited by 43
Unraveling the Genotype‐Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity‐Related Cardiac Defects as a Major Disease Modifier
Nollet, E. E., Westenbrink, B. D., de Boer, R. A., Kuster, D. W. D., & van der Velden, J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018641 · Cited by 44
Self-citation
Genotype‐specific pathogenic effects in human dilated cardiomyopathy
Bollen, I. A. E., Schuldt, M., Harakaľová, M., Vink, A., Asselbergs, F. W., Pinto, J. R., Krüger, M., Kuster, D. W. D., & van der Velden, J. (2017) · The Journal of Physiology · doi:10.1113/jp274145 · Cited by 43
Self-citation
The embryological basis of subclinical hypertrophic cardiomyopathy
Captur, G., Ho, C. Y., Schlossarek, S., Kerwin, J. M., Mirabel, M., Wilson, R. J., Rosmini, S., Obianyo, C., Réant, P., Bassett, P., et al. (2016) · Scientific Reports · doi:10.1038/srep27714 · Cited by 42
Self-citation
Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation
Mamidi, R., Gresham, K. S., & Stelzer, J. E. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00461 · Cited by 40
Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy
Dorsch, L. M., Schuldt, M., dos Remedios, C. G., Schinkel, A. F. L., de Jong, P. L., Michels, M., Kuster, D. W. D., Brundel, B. J. J. M., & van der Velden, J. (2019) · Cells · doi:10.3390/cells8070741 · Cited by 40
Self-citation
S ‐glutathiolation impairs phosphoregulation and function of cardiac myosin‐binding protein C in human heart failure
Σταθοπούλου, Κ., Wittig, I., Heidler, J., Piasecki, A., Richter, F. M., Diering, S., van der Velden, J., Buck, F., Donzelli, S., Schröder, E., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500048 · Cited by 39
Self-citation
Ion Channel Impairment and Myofilament Ca2+ Sensitization: Two Parallel Mechanisms Underlying Arrhythmogenesis in Hypertrophic Cardiomyopathy
Santini, L., Coppini, R., & Cerbai, E. (2021) · Cells · doi:10.3390/cells10102789 · Cited by 38
The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
Edelberg, J. M., Sehnert, A. J., Mealiffe, M. E., del Rio, C. L., & McDowell, R. S. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00532-x · Cited by 38
Monophosphorylation of cardiac troponin-I at Ser-23/24 is sufficient to regulate cardiac myofibrillar Ca2+ sensitivity and calpain-induced proteolysis
Martín-Garrido, A., Biesiadecki, B. J., Salhi, H. E., Shaifta, Y., dos Remedios, C. G., Ayaz‐Güner, Ş., Cai, W., Ge, Y., Avkiran, M., & Kentish, J. C. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001292 · Cited by 37
The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform
Soetkamp, D., Raedschelders, K., Mastali, M., Sobhani, K., Bairey Merz, C. N., & Van Eyk, J. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1387054 · Cited by 36
Cardiac myosin-binding protein-C is a critical mediator of diastolic function
Tong, C. W.-C., Nair, N., Doersch, K., Liu, Y., & Rosas, P. C. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1442-1 · Cited by 36
Modelling sarcomeric cardiomyopathies with human cardiomyocytes derived from induced pluripotent stem cells
Sewanan, L. R., & Campbell, S. G. (2019) · The Journal of Physiology · doi:10.1113/jp276753 · Cited by 38
Troponin I phosphorylation in human myocardium in health and disease
Wijnker, P. J. M., Murphy, A. M., Stienen, G. J. M., & van der Velden, J. (2014) · Netherlands Heart Journal · doi:10.1007/s12471-014-0590-4 · Cited by 36
Self-citation
Long Term Ablation of Protein Kinase A (PKA)-mediated Cardiac Troponin I Phosphorylation Leads to Excitation-Contraction Uncoupling and Diastolic Dysfunction in a Knock-in Mouse Model of Hypertrophic Cardiomyopathy
Dweck, D., Sanchez‐Gonzalez, M. A., Chang, A. N., Dulce, R. A., Badger, C.-D., Koutnik, A. P., Ruiz, E. L., Griffin, B. L., Liang, J., Kabbaj, M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.561472 · Cited by 36
HSC70 is a chaperone for wild-type and mutant cardiac myosin binding protein C
Glazier, A. A., Hafeez, N., Mellacheruvu, D., Basrur, V., Nesvizhskii, A. I., Lee, L. M., Shao, H., Tang, V. T., Yob, J. M., Gestwicki, J. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99319 · Cited by 35
Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients, mouse models and human engineered heart tissue
Wijnker, P. J. M., & van der Velden, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165774 · Cited by 34
Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function inMybpc3-targeted HCM mouse model
Najafi, A., Sequeira, V., Helmes, M., Bollen, I. A. E., Goebel, M., Regan, J. A., Carrier, L., Kuster, D. W. D., & van der Velden, J. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw026 · Cited by 34
Self-citation
Familial hypertrophic cardiomyopathy: functional variance among individual cardiomyocytes as a trigger of FHC-phenotype development
Brenner, B., Seebohm, B., Tripathi, S., Montag, J., & Kraft, T. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00392 · Cited by 33
The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM
Piroddi, N., Witjas‐Paalberends, E. R., Ferrara, C., Ferrantini, C., Vitale, G., Scellini, B., Wijnker, P. J. M., Sequeira, V., Dooijes, D., dos Remedios, C. G., et al. (2018) · The Journal of General Physiology · doi:10.1085/jgp.201812160 · Cited by 31
Self-citation
The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP‐C
Suay‐Corredera, C., & Alegre‐Cebollada, J. (2022) · FEBS Letters · doi:10.1002/1873-3468.14301 · Cited by 31
Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy
Kraft, T., & Montag, J. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-019-02260-9 · Cited by 29
Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice
Najafi, A., Schlossarek, S., van Deel, E. D., van den Heuvel, N., Güçlü, A., Goebel, M., Kuster, D. W. D., Carrier, L., & van der Velden, J. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1570-7 · Cited by 28
Self-citation
Myofilament Remodeling and Function Is More Impaired in Peripartum Cardiomyopathy Compared with Dilated Cardiomyopathy and Ischemic Heart Disease
Bollen, I. A. E., Ehler, E., Fleischanderl, K., Bouwman, F., Kempers, L., Ricke‐Hoch, M., Hilfiker‐Kleiner, D., dos Remedios, C. G., Krüger, M., Vink, A., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.08.022 · Cited by 27
Self-citation
Differences in the regulation of RyR2 from human, sheep, and rat by Ca2+ and Mg2+ in the cytoplasm and in the lumen of the sarcoplasmic reticulum
Walweel, K., Li, J., Molenaar, P., Imtiaz, M. S., Quail, A., dos Remedios, C. G., Beard, N. A., Dulhunty, A. F., Helden, D. F. V., & Laver, D. R. (2014) · The Journal of General Physiology · doi:10.1085/jgp.201311157 · Cited by 25
Cardiac myosin-binding protein C: hypertrophic cardiomyopathy mutations and structure–function relationships
Sequeira, V., Witjas‐Paalberends, E. R., Kuster, D. W. D., & van der Velden, J. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1400-3 · Cited by 24
Self-citation
Cardiac Myosin Binding Protein-C Phosphorylation Mitigates Age-Related Cardiac Dysfunction
Rosas, P. C., Warren, C. M., Creed, H. A., Trzeciakowski, J. P., Solaro, R. J., & Tong, C. W.-C. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.06.003 · Cited by 22
Omecamtiv Mecarbil Abolishes Length-Mediated Increase in Guinea Pig Cardiac Myofiber Ca2+ Sensitivity
Gollapudi, S. K., Reda, S. M., & Chandra, M. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.07.002 · Cited by 22
Cardiomyocyte Hypocontractility and Reduced Myofibril Density in End-Stage Pediatric Cardiomyopathy
Bollen, I. A. E., van der Meulen, M., de Goede, K. E., Kuster, D. W. D., Dalinghaus, M., & van der Velden, J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.01103 · Cited by 22
Self-citation
Point mutations in the tri-helix bundle of the M-domain of cardiac myosin binding protein-C influence systolic duration and delay cardiac relaxation
van Dijk, S. J., Kooiker, K. B., Napierski, N. C., Touma, K., Mazzalupo, S., & Harris, S. P. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.05.001 · Cited by 21
Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue
Dutsch, A., Wijnker, P. J. M., Schlossarek, S., Friedrich, F. W., Krämer, E., Braren, I., Hirt, M. N., Brenière‐Letuffe, D., Rhoden, A., Mannhardt, I., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54665-2 · Cited by 20
Self-citation
The Heartbreak of Psoriasis
Benson, M., & Frishman, W. H. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000048 · Cited by 20
Feasibility and Significance of Preclinical Diagnosis in Hypertrophic Cardiomyopathy
Efthimiadis, G. K., Pagourelias, E. D., Hadjimiltiades, S., Meditskou, S., Karvounis, H. I., & McKenna, W. J. (2015) · Cardiology in Review · doi:10.1097/crd.0000000000000076 · Cited by 20
Epigallocatechin-3-Gallate Accelerates Relaxation and Ca2+ Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice
Friedrich, F. W., Flenner, F., Nasib, M., Thomas Eschenhagen, A., & Carrier, L. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00607 · Cited by 19
Self-citation
The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy‐Progress and Novel Therapeutic Opportunities
Mohamed, I. A., Krishnamoorthy, N., Nasrallah, G. K., & Da'as, S. I. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25639 · Cited by 19
Sarcomere length affects Ca2+ sensitivity of contraction in ischemic but not non-ischemic myocardium
Tanner, B. C. W., Awinda, P. O., Agonias, K. B., Attili, S., Blair, C. A., Thompson, M. S., Walker, L. A., Kampourakis, T., & Campbell, K. S. (2022) · The Journal of General Physiology · doi:10.1085/jgp.202213200 · Cited by 17
Mechano-energetic uncoupling in hypertrophic cardiomyopathy: Pathophysiological mechanisms and therapeutic opportunities
Sequeira, V., Waddingham, M. T., Tsuchimochi, H., Maack, C., & Pearson, J. T. (2023) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2023.100036 · Cited by 18
Substrate mechanics unveil early structural and functional pathology in iPSC micro-tissue models of hypertrophic cardiomyopathy
Guo, J., Jiang, H., Schuftan, D. R., Moreno, J. D., Ramahdita, G., Aryan, L., Bhagavan, D., Silva, J. R., & Huebsch, N. (2024) · iScience · doi:10.1016/j.isci.2024.109954 · Cited by 16
Surviving the infarct: A profile of cardiac myosin binding protein‐C pathogenicity, diagnostic utility, and proteomics in the ischemic myocardium
Lynch, T. L., & Sadayappan, S. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400011 · Cited by 16
Self-citation
Feline myocardial transcriptome in health and in hypertrophic cardiomyopathy—A translational animal model for human disease
Joshua, J., Caswell, J., O’Sullivan, M. L., Wood, G. A., & Fonfara, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283244 · Cited by 15
ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study)
Güçlü, A., Germans, T., Witjas‐Paalberends, E. R., Stienen, G. J. M., Brouwer, W. P., Harms, H. J., Marcus, J. T., Vonk, A. B. A., Stooker, W., Yılmaz, A., et al. (2013) · Netherlands Heart Journal · doi:10.1007/s12471-013-0478-8 · Cited by 15
Self-citation
Analysis of Contractile Function of Permeabilized Human Hypertrophic Cardiomyopathy Multicellular Heart Tissue
Kresin, N., Stücker, S., Krämer, E., Flenner, F., Mearini, G., Münch, J., Patten, M., Redwood, C. S., Carrier, L., & Friedrich, F. W. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00239 · Cited by 15
Self-citation
Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with MYBPC3 mutations
van Dijk, S. J., Boontje, N. M., Heymans, M. W., ten Cate, F. J., Michels, M., dos Remedios, C. G., Dooijes, D., van Slegtenhorst, M. A., van der Velden, J., & Stienen, G. J. M. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1391-0 · Cited by 15
Self-citation
Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3 in the Netherlands
Hilderink, S., Schuldt, M., Goebel, M., Jansen, V. J., Manders, E., Moorman, S., Dorsch, L. M., van Steenbeek, F. G., van der Velden, J., & Kuster, D. W. D. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.10.008 · Cited by 14
Self-citation
Stochastic allelic expression as trigger for contractile imbalance in hypertrophic cardiomyopathy
Montag, J., & Kraft, T. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00719-z · Cited by 12
Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
Stücker, S., Kresin, N., Carrier, L., & Friedrich, F. W. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00558 · Cited by 11
Self-citation
Transcriptional bursts and heterogeneity among cardiomyocytes in hypertrophic cardiomyopathy
Burkart, V., Kowalski, K., Aldag-Niebling, D., Beck, J., Frick, D. A., Holler, T., Radocaj, A., Piep, B., Zeug, A., Hilfiker‐Kleiner, D., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.987889 · Cited by 11
Transcriptome Profile Identifies Actin as an Essential Regulator of Cardiac Myosin Binding Protein C3 Hypertrophic Cardiomyopathy in a Zebrafish Model
Da'as, S. I., Hasan, W., Salem, R., Younes, N., Abdelrahman, D., Mohamed, I. A., Aldaalis, A., Temanni, R., Mathew, L. S., Lorenz, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168840 · Cited by 9
Pathogenesis associated with a restrictive cardiomyopathy mutant in cardiac troponin T is due to reduced protein stability and greatly increased myofilament Ca2+ sensitivity
Parvatiyar, M. S., & Pinto, J. R. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.09.029 · Cited by 7
Echocardiographic evaluation of pre-diagnostic development in young relatives genetically predisposed to hypertrophic cardiomyopathy
Jensen, M. K., Havndrup, O., Christiansen, M., Andersen, P. S., Raja, A. A., Køber, L., & Bundgaard, H. (2015) · International journal of cardiac imaging · doi:10.1007/s10554-015-0723-x · Cited by 6
Nonsense mediated decay factor UPF3B is associated with cMyBP-C haploinsufficiency in hypertrophic cardiomyopathy patients
Burkart, V., Kowalski, K., Disch, A., Hilfiker‐Kleiner, D., Lal, S., dos Remedios, C. G., Perrot, A., Zeug, A., Ponimaskin, E. G., Kosanke, M., et al. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.09.008 · Cited by 6
Prospects for remodeling the hypertrophic heart with myosin modulators
Sewanan, L. R., & Shimada, Y. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1051564 · Cited by 6

Authors: van Dijk, S. J., Paalberends, E. R., Najafi, A., Michels, M., Sadayappan, S., Carrier, L., Boontje, N. M., Kuster, D. W. D., van Slegtenhorst, M., Dooijes, D., dos Remedios, C., ten Cate, F. J., Stienen, G. J. M., & van der Velden, J.
Affiliations: From the Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands (S.J.D., E.R.P., A.N., N.M.B., D.W.D.K., G.J.M.S., J.V.); Department of Physics and Astronomy, VU University Amsterdam, De Boelelaan 1081, Amsterdam, The Netherlands (G.J.M.S.); Thorax Center (M.M., F.J.C.) and Clinical Genetics (M.S.), Erasmus Medical Center Rotterdam, The Netherlands; Department of Cell and Molecular Physiology, Loyola University Chicago, Chicago, IL ...
The University of Sydney (AU)
ORCID: Michels, Michelle
Sadayappan, Sakthivel
Carrier, Lucie
Kuster, Diederik W.D.
Dooijes, Dennis
Stienen, Ger J.M.
Venue: Circulation: Heart Failure
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2012-01
Volume: 5
Issue: 1
Pages: 36-46
ISSN: 1941-3289 (ISSN-L)
1941-3297
DOI: 10.1161/circheartfailure.111.963702
OpenAlex: W2102903858
Cited by: 124
References: 51
Citations by year: 2026: 5 · 2025: 4 · 2024: 1 · 2023: 7 · 2022: 10 · 2021: 4 · 2020: 4 · 2019: 9 · 2018: 14 · 2017: 8 · 2016: 11 · 2015: 9 · 2014: 20 · 2013: 15 · 2012: 3
FWCI: 8.34
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Circulation Heart Failure (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
Pure Amsterdam UMC (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders: Erasmus Medisch Centrum
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: hypertrophic cardiomyopathy, MYBPC3 mutation, diastolic dysfunction, myosin binding protein C, troponin I phosphorylation, myofilament calcium sensitivity, length-dependent activation, protein kinase A, contractile dysfunction, sarcomere length
MeSH terms: Myosin Binding Protein C, Adult, Aged, Blood Pressure, Calcium, Cardiomyopathy, Hypertrophic, Carrier Proteins, Diastole, Female, Humans, Male, Middle Aged, Mutation, Myocardial Contraction, Phosphorylation, Sarcomeres, Systole, Ventricular Function, Left, Cyclic AMP-Dependent Protein Kinases, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Contractile Dysfunction Irrespective of the Mutant Protein in Human Hypertrophic Cardiomyopathy With Normal Systolic Function

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks